A case series of efavirenz induced gynaecomastia
DOI:
https://doi.org/10.18203/2349-3933.ijam20212412Keywords:
HIV, HAART, Efavirenz, GynaecomastiaAbstract
The prognosis of HIV infection has significantly changed following the introduction of highly active anti-retroviral therapy by reducing AIDS related morbidity and mortality. At the same time, HAART is documented for its side effects. Gynaecomastia is a less documented side effect of a commonly used ART drug efavirenz. There are only few case reports of HAART-induced gynaecomastia in resource limited settings. Initially gynaecomastia related to HAART in HIV patients was thought due to lipodystrophy and was termed as pseudogynaecomastia. Later, few case reports of efavirenz related gynaecomastia were published after ruling out other causes of gynaecomastia. All other causes of gynaecomastia were ruled out in our patients too. The incidence of gynaecomastia is increasing in men with HIV on HAART therapy, proper identification and management will promote better drug adherence. The present study presented a series of two cases that developed ultrasound confirmed gynaecomastia following efavirenz containing HAART.
References
Qazi NA, Morlese JF, King DM, Ahmad RS, Gazzard BG, Nelson MR. Gynaecomastia without lipodystrophy in HIV-1-seropositive patients onefavirenz: an alternative hypothesis. AIDS. 2002;16(3):506-7.
Rahim S, Ortiz O, Maslow M, Holzman R. A case control study of gynecomastia in HIV-1-infected patients receiving HAART. AIDS Read. 2004;14(1):35-40.
Manfredi R, Calza L, Chiodo F. Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. J Acquir Immune Defic Syndr. 2004;35(5):492-502.
Jover F, Cuadrado JM, Roig P, Rodriguez M, Andreu L, Merino J. Efavirenz-associated gynecomastia: report of five cases and review of the literature. Breast J. 2004;10(3):244-6.
Biglia A, Blanco JL, Martínez E, Domingo P, Casamitjana R, Sambeat M, et al. Gynecomastia among HIV-infected patients is associated with hypogonadism: a case-control study. Clin Infect Dis. 2004;39(10):1514-9.
Sikora MJ, Rae JM, Johnson MD, Desta Z. Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growth. HIV Med. 2010;11(9):603-7.
Deepinder F, Braunstein GD. Drug-induced gynecomastia: an evidence-based review. Expert Opin Drug Saf. 2012;11(5):779-95.
Oche OA, Patricia AA, Peter NE, Halima MS, Raphael OO, Eunice A, et al. Efavirenz-induced gynaecomastia in HIV-infected Nigerian men: A report of six cases. J Med Medical Sci. 2011;2(11):1221-4.
Ishwar SH, Mahabaleshwar SM, Basith LK, Vinaykumar BH. Efavirenz-induced gynaecomastia in hiv infected males: a report of 2 cases. J Evid. Based Med Healthc. 2016;3(68):3729-32.
Anders F, Richard L, Guglielmo R, Anna E, Fabio S, Gennaro S. Gynecomastia: a systematic review. J Plast Surg Hand Surg. 2015;49(6):311-8.
